57-96-5 | 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione

Packsize	Purity	Availability	Price	Discounted Price
250mg	97%	in stock	$13.00	$9.00
1g	97%	in stock	$15.00	$10.00
25g	98%	in stock	$18.00	$13.00

Description

• Catalog Number: AB57149
• Chemical Name: 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
• CAS Number: 57-96-5
• Molecular Formula: C23H20N2O3S
• Molecular Weight: 404.4815
• MDL Number: MFCD00057279
• SMILES: O=C1N(c2ccccc2)N(C(=O)C1CCS(=O)c1ccccc1)c1ccccc1

Computed Properties

• Complexity: 571
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 6
• Undefined Atom Stereocenter Count: 1
• XLogP3: 2.3

Literature

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Discovery of small molecule human FPR1 receptor antagonists.

  Bioorganic & medicinal chemistry letters 20110515

• Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Interactions of urate transporter URAT1 in human kidney with uricosuric drugs.

  Nephrology (Carlton, Vic.) 20110201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.

  Bioorganic & medicinal chemistry 20101101

• Adherence with urate-lowering therapies for the treatment of gout.

  Arthritis research & therapy 20090101

• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  Journal of medicinal chemistry 20080612

• Uric acid lowering therapy: prescribing patterns in a large cohort of older adults.

  Annals of the rheumatic diseases 20080501

• MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.

  Molecular cancer therapeutics 20080501

• 2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies.

  Bioorganic & medicinal chemistry letters 20080115

• HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20080101

• Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity.

  Journal of medicinal chemistry 20071227

• Molecular epidemiology of malaria in Cameroon. XXVI. Twelve-year in vitro and molecular surveillance of pyrimethamine resistance and experimental studies to modulate pyrimethamine resistance.

  The American journal of tropical medicine and hygiene 20070801

• Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells.

  Drug metabolism and disposition: the biological fate of chemicals 20070601

• Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins.

  European journal of pharmacology 20070410

• Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20070301

• Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay.

  Journal of biomolecular screening 20070301

• In silico prediction of pregnane X receptor activators by machine learning approaches.

  Molecular pharmacology 20070101

• Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9.

  Drug metabolism and disposition: the biological fate of chemicals 20061201

• Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.

  Drug metabolism and disposition: the biological fate of chemicals 20061001

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Clinical trials of uric acid lowering for coronary heart disease risk reduction.

  The American journal of medicine 20060401

• Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones.

  Bioorganic & medicinal chemistry letters 20060215

• Macrophage uptake and recycling of ascorbic acid: response to activation by lipopolysaccharide.

  Free radical biology & medicine 20051201

• Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20051101

• Combined effects of GSTP1 and MRP1 in melanoma drug resistance.

  British journal of cancer 20050725

• Chondrocyte transport and concentration of ascorbic acid is mediated by SVCT2.

  Biochimica et biophysica acta 20050630

• High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands.

  Journal of biomolecular screening 20050601

• UDP-glucuronosyltransferases and clinical drug-drug interactions.

  Pharmacology & therapeutics 20050401

• Ascorbate uptake in pig coronary artery endothelial cells.

  Molecular and cellular biochemistry 20050301

• Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.

  British journal of pharmacology 20041201

• Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter.

  Journal of the American Society of Nephrology : JASN 20041101

• Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.

  European journal of clinical pharmacology 20040801

• Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects.

  Molecular pharmacology 20040401

• Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

  Drug metabolism and disposition: the biological fate of chemicals 20040301

• Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones.

  Bioorganic & medicinal chemistry letters 20040119

• Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity.

  The Journal of pharmacology and experimental therapeutics 20040101

• Differential effects of glucose on dehydroascorbic acid transport and intracellular ascorbate accumulation in astrocytes and skeletal myocytes.

  Brain research 20031212

• Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transport.

  Toxicology and applied pharmacology 20031115

• Identification and prediction of promiscuous aggregating inhibitors among known drugs.

  Journal of medicinal chemistry 20031009

• Functional expression of the multidrug resistance protein 1 in microglia.

  The Journal of pharmacology and experimental therapeutics 20031001

• UV or X-irradiation increases the cytoplasmic accumulation of rhodamine 123 in various cancer cell lines.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20030801

• Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).

  Molecular pharmacology 20030201

• Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.

  Archives of biochemistry and biophysics 20030101

• Accumulation of intracellular ascorbate from dehydroascorbic acid by astrocytes is decreased after oxidative stress and restored by propofol.

  Glia 20020801

• CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20020701

• Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.

  Cancer research 20020601

• Free radical scavenging properties of sulfinpyrazone.

  Free radical research 20020601

• Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2).

  Pharmacology 20020101

• Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).

  The Journal of biological chemistry 20011207

• Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity.

  The Journal of biological chemistry 20011012

• Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.

  Cancer research 20010715

• Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s.

  Drug metabolism and disposition: the biological fate of chemicals 20010501

• A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro.

  Xenobiotica; the fate of foreign compounds in biological systems 19990301

• Acute renal failure due to sulfinpyrazone.

  The American journal of the medical sciences 19980501

• Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene.

  European journal of drug metabolism and pharmacokinetics 19970101

• Antiplatelet therapy in the prevention of stroke.

  Drugs 19910101

• Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase.

  The Journal of clinical investigation 19900201

• Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 19860501

• Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.

  European journal of clinical pharmacology 19860101

• [Acute tubulo-interstitial nephropathy associated with ingestion of sulfinpyrazone].

  Presse medicale (Paris, France : 1983) 19850223

• Sulfinpyrazone: risk for renal insufficiency.

  Archives of internal medicine 19840301

• [Acute interstitial nephritis and kidney failure requiring dialysis after sulfinpyrazone therapy].

  Acta medica Austriaca 19840101

• Acute renal failure secondary to sulfinpyrazone treatment after myocardial infarction.

  Nephron 19840101

• Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis-effect of sulphinpyrazone treatment.

  Thrombosis and haemostasis 19831230

• Sulfinpyrazone-associated acute renal failure.

  Clinical nephrology 19830701

• Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction.

  Clinical nephrology 19830301

• Oliguric acute renal failure after treatment with sulfinpyrazone.

  Clinical nephrology 19830101

• [Sulfinpyrazone-associated renal failure (author's transl)].

  Deutsche medizinische Wochenschrift (1946) 19820709

• Non oliguric acute renal failure after treatment with sulfinpyrazone.

  Clinical nephrology 19820501

• Acute renal failure following sulfinpyrazone therapy.

  South Dakota journal of medicine 19820401

• Sulphinpyrazone--induced decrease in renal function: a review of reports with discussion of pathogenesis.

  Acta clinica Belgica 19820101

• Renal dysfunction due to anturane.

  The New England journal of medicine 19811105

• Acute renal dysfunction due to sulfinpyrazone therapy in post-myocardial infarction cardiomegaly: reversible hypersensitive interstitial nephritis.

  American heart journal 19810801

• Renal dysfunction due to anturan.

  The New England journal of medicine 19810709

• Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis.

  Japanese heart journal 19810701

• Sulfinpyrazone induced uric acid urolithiasis with acute renal failure.

  Connecticut medicine 19810701

• Sulphinpyrazone-induced acute renal failure.

  British medical journal (Clinical research ed.) 19810221

• [Acute renal failure induced by sulfinpyrazone (author's transl)].

  Nephrologie 19810101

• Are agents affecting platelet functions clinically useful?

  The American journal of medicine 19761201

• Abnormalities of urinary sediment and renal failure following sulfinpyrazone therapy.

  Archives of internal medicine 19760901

• Acute myelomonocytic leukaemia and multiple myeloma after sulphinpyrazone and colchicine treatment of gout.

  British medical journal 19760710